≡

Multiplex Assay Kit for Prekallikrein (PK) ,etc. by FLIA (Flow Luminescence Immunoassay)

KLKB1; KLK3; Fletcher Factor; Kallikrein B,Plasma; Kininogenin; Plasma prekallikrein

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Prekallikrein (PK) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Prekallikrein (PK) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Prekallikrein (PK) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Prekallikrein (PK) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 96-103 99
EDTA plasma(n=5) 90-97 93
heparin plasma(n=5) 92-99 96

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Prekallikrein (PK) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Prekallikrein (PK) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Prekallikrein (PK) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 86-93% 93-101% 86-95% 84-91%
EDTA plasma(n=5) 78-96% 90-98% 95-103% 80-101%
heparin plasma(n=5) 80-99% 84-98% 85-104% 78-90%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:PK) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Int J Immunopathol Pharmacol Altered activities of kininase II, an angiotensin converting enzyme, prekallikrein, and nitric oxide in Kuwaiti patients with type 2 diabetes PubMed: 25964383
Thromb Res Factor XII–mediated contact activation related to poor prognosis in disseminated intravascular coagulation PubMed: 26706311
Thrombosis Research Factor XII-mediated contact activation related to poor prognosis in disseminated intravascular coaCavia (Guinea pig )lation Pubmed:26706311
Annals of Laboratory Medicine The First Case of Congenital Prekallikrein Deficiency in Korea With a Novel Pathogenic Variant (c. 1198G> T) Pubmed: 30430790
J Cell Mol Med Huaier shows anti©\cancer activities by inhibition of cell growth, migration and energy metabolism in lung cancer through PI3K/AKT/HIF©\1¦Á pathway 33377619
J Thromb Thrombolysis Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors Pubmed:34993714
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPB801Hu01 Recombinant Prekallikrein (PK) Positive Control; Immunogen; SDS-PAGE; WB.
PAB801Hu01 Polyclonal Antibody to Prekallikrein (PK) WB; IHC; ICC; IP.
MAB801Hu22 Monoclonal Antibody to Prekallikrein (PK) WB; IHC; ICC; IP.
SEB801Hu ELISA Kit for Prekallikrein (PK) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB801Hu Multiplex Assay Kit for Prekallikrein (PK) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.